Decentralized Visits in Rare Disease Studies
Learn how ProPharma helped implement and execute decentralized visits for a pediatric rare disease study.
The COVID-19 pandemic caused major disruption to many clinical trials and the participants receiving treatment. The risk of exposure for pediatric rare disease patients and their families was particularly challenging and stressful. Reduced travel options compounded by the risk for exposure during travel or at the Site, affected the entire family.
Read more about how ProPharma worked with the sponsor to implement and execute decentralized visits so that patients could continue their study as planned.
Related Resources
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...
Navigating the Generic Drug Application and Approval Process
Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...